Validating the Diagnostic Accuracy of Mediview 2.0 Software as an Image Analysis Tool of Meibomian Glands
NCT ID: NCT01991132
Last Updated: 2015-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2013-12-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Knowledge of the health of meibomian glands is useful, especially in the diagnosis of Meibomian Gland Dysfunction (MGD). Studies have shown that MGD is one of the most common causes of evaporative dry eye.
Mediview 2.0 is a software that has been programmed to semi-automatically classify meibograph images taken via non-contact meibography. This software is collaboration with Shanghai MediWorks Precision Instruments Co., Ltd. The algorithm used was developed by a collaboration between Agency for Science, Technology and Research (A\*STAR) and Singapore Eye Research Institute (SERI).
This current study aims to validate the diagnostic accuracy of Mediview 2.0 in assessing the health of meibomian glands of patients, against a trained clinician. We aim to recruit 100 participants for this study.
Once this software is found to be valid, a trained technician could be taught how to capture the images and hence leaving the doctors with more time to focus on clinical assessment and treatment instead. Therefore, this study has the potential to increase efficiency in the clinics.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fast Infrared Meibography (Photography)
NCT02596919
Reproducibility of LipiView Ocular Surface Interferometer (LipiView) for Measuring Tear Lipid Layer Thickness
NCT01933165
Repeatability and Agreement of Anterior Segment Optical Coherence Tomography (AS-OCT) and Thermography
NCT01479790
Reproducibility of Anterior Segment Optical Coherence Tomography (AS-OCT) for Imaging Conjunctivochalasis
NCT01933178
Tear Layer Lipid Thickness in Pterygium Patient Before and After Surgery
NCT02160769
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is recommended that the diagnosis of MGD be made by assessing ocular symptoms, lid morphology, mebomian gland mass, gland expressibility, lipid layer thickness and meibography. In meibography, the structure of the meibomian glands, including the ducts and acini can be observed. Photographic documentation of the meibomian gland is also possible under specialised illumination techniques.
There are two types of meibography currently in use- contact meibography and non-contact meibography. Non-contact meibography is advantageous over contact meibography as it is more comfortable for patients. In non-contact meibography, the slit-lamp microscope is equipped with an IR charge-coupled (CCD) device video camera and an IR transmitting filter. During the procedure, IR light is projected onto the inverted eyelid of the subject and the image of the eyelid captured by a camera.
Currently, skilled clinicians analyse images obtained via non-contact meibography manually to determine the health of the patient's eyelid. Through a collaborative project between scientists from bioinformatics institute, A\*STAR, Singapore (Dr Lee Hwee Kuan) and SERI, semi-automatic algorithms for classifying meibographs into healthy and unhealthy have been previously developed. The commercial partner for this project, Mediworks, China, has incorporated these algorithms into the Mediview 2.0 software. This software consists of modules for acquiring meibography images as well as for analysing these images. Provided a user draws the outline of the tarsal plate on the captured image, the software is able to classify images into two categories- Healthy and Unhealthy without the aid of a skilled clinician. A trained technician could be taught how to capture the images and hence leaving the doctor with more time to focus on clinical assessment and treatment.
However, the accuracy and reproducibility of this software should be validated against a clinical assessor just as in the original algorithms. We propose to recruit 50 healthy volunteers and 50 patients from SNEC clinics and from public.
Clinical importance Should this modality of imaging be shown to be repeatable, it can be incorporated into current protocol/workflow for assessment and monitoring of Meibomian Gland Dysfunction and treatment progress in our centre. The images captured in this project can also be used for validating further updates of the Mediworks software, since the hardware will remain unchanged in the future.
Study Objectives and Purpose The primary purpose is to validate Mediview 2.0 software as an objective tool in assessing the health of meibomian glands.
The specific aims include assessing a., the accuracy of Mediview 2.0 in classifying meibograph images (into Healthy and Unhealthy categories) and b., reproducibility of the classifications.
Study design:
Prospective study
Rationale:
Mediview 2.0 is a newly developed software and has yet been validated as a tool for assessment of the health of meibomian glands.
Methods:
Participants and target sample size 50 healthy volunteers and 50 patients aged 21 to 99 years will be recruited for this study. They are outpatients and accompanying relatives from the Singapore National Eye Centre. Permission would be sought from the attending doctors before subjects are being recruited. Informed written consent will be obtained from all participants.
Visit schedules One visit is required for participants. In general, they will not have to come for additional visits if they are recruited whilst on a scheduled clinical appointment for other reasons. In exceptional cases, if the meibography cannot be performed on the same day, participants would be given the option of coming on another suitable day for this study.
Duration of study:
12 months.
Procedures:
1. Imaging of Meibomian Gland During the imaging of each eye, participants will be required to place their chins on a chin rest on the slit-lamp microscope. The upper eyelids of the participant will be in turn everted and an image of meibomian glands present on the eyelid will be captured. This is also performed for the lower eyelids. This is a non-invasive technique and the camera and IR lamp will not touch the patient. During each eversion of eyelid, optometrist will acquire 3 images at one time. Thereafter, Mediview 2.0 software will proceed to analyse the image into healthy and unhealthy glands.
Throughout all measurements, all parameters of the meibographer, (such as light intensity, magnification of eyelid) will be kept constant.
2. Analysis of Image of Meibomian Gland The images taken above will be exported and assessed by another optometrist who is unaware of the classification of the image by Mediview. This assessor will classify the images into healthy and unhealthy. Results between the Mediview 2.0 software and the optometrist will be assessed. Should there be any disagreement on the results, a 3rd clinician will be involved in the validation.
Statistical analysis:
1. Comparison between software classification and human classification Cohen's kappa coefficient will be calculated to assess the agreement between these two ratings. For interpretation of the calculated statistic, we use recommendations from Landis and Koch, who characterized values \< 0 as indicating no agreement and 0-0.20 as slight, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial, and 0.81-1 as almost perfect agreement.
2. Comparison between the first and second software classifications Similarly we will use the kappa coefficient to evaluate the agreements between the first and second classifications made by the software.
Expected outcomes:
The classification of meibograph images from Mediview 2.0 should show good agreement with the assessment by the skilled clinician. Similarly classifications of the meibographs taken on the same day for the same eyes should show good agreement.
Potential problems No potential problems are expected for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MediView 2.0 software
MediView 2.0 software
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MediView 2.0 software
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
21 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Singapore National Eye Centre
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Louis Tong
Clinician-Scientist, Senior Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Louis Tong, PhD
Role: PRINCIPAL_INVESTIGATOR
Singapore National Eye Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Singapore Eye Research Institute
Singapore, Singapore, Singapore
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013/737/A
Identifier Type: OTHER
Identifier Source: secondary_id
R1059/74/2013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.